Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Rb Hlth Company Profile

Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for RB HLTH, and what generic and branded alternatives to RB HLTH drugs are available?

RB HLTH has four approved drugs.

Summary for Rb Hlth

US Patents:	0
Tradenames:	4
Ingredients:	4
NDAs:	4

Drugs and US Patents for Rb Hlth

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-001	Apr 29, 2004		OTC	Yes	Yes		⤷ Sign up for a Free Trial				⤷ Sign up for a Free Trial
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-001	Jul 12, 2002		OTC	Yes	No		⤷ Sign up for a Free Trial				⤷ Sign up for a Free Trial
Rb Hlth	MUCINEX D	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021585-001	Jun 22, 2004		OTC	Yes	No		⤷ Sign up for a Free Trial				⤷ Sign up for a Free Trial
Rb Hlth	MUCINEX	guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021282-002	Dec 18, 2002		OTC	Yes	Yes		⤷ Sign up for a Free Trial				⤷ Sign up for a Free Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Rb Hlth

Subscribe to access the full database, or Sign up for a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rb Hlth	MUCINEX DM	dextromethorphan hydrobromide; guaifenesin	TABLET, EXTENDED RELEASE;ORAL	021620-002	Apr 29, 2004	6,372,252	⤷ Sign up for a Free Trial
Rb Hlth	DELSYM	dextromethorphan polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	018658-001	Oct 8, 1982	4,221,778	⤷ Sign up for a Free Trial
Rb Hlth	MUCINEX D	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021585-001	Jun 22, 2004	7,838,032	⤷ Sign up for a Free Trial
Rb Hlth	MUCINEX D	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021585-001	Jun 22, 2004	6,955,821	⤷ Sign up for a Free Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for RB HLTH drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Suspension	30 mg/5 mL	➤ Subscribe	2009-01-12
➤ Subscribe	Extended-release Tablets	600 mg/30 mg and 1200 mg/60 mg	➤ Subscribe	2008-12-17
➤ Subscribe	Extended-release Tablets	600 mg and 1.2 gm	➤ Subscribe	2006-06-09

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Rb Hlth

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Medtronic

Harvard Business School

Mallinckrodt

McKinsey

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.